Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
<h4>Unlabelled</h4>Vaccination against influenza is an important means of reducing morbidity and mortality in subjects at risk. The prevalent viral strains responsible for seasonal epidemics usually change annually, but the WHO recommendations for the 2011/2012-season in the Northern hem...
Main Authors: | Micha Loebermann, Ulrich Voss, Seetha Meyer, Dietrich Bosse, Carlos Fritzsche, Sebastian Klammt, Silvius Frimmel, Diana Riebold, Emil C Reisinger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23976960/?tool=EBI |
Similar Items
-
Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011-02-01) -
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
by: Cristina Carter, et al.
Published: (2019-01-01) -
Preparation of niosomal nanostructure containing Brucella trivalent immunogen as a vaccine candidate
by: Fahimeh Sharif, et al.
Published: (2023-01-01) -
Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
by: Kei Nakashima, et al.
Published: (2017-03-01) -
Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
by: Zhaojun Mo, et al.
Published: (2017-06-01)